

# GETTING YOUR T2DM PATIENTS IN TUNE WITH CONTROL

## A 2-step guide to initiate and titrate Toujeo to individualized goal

### 1. The starting dose is based on patients' prior treatment<sup>1</sup>:

#### Insulin-naïve



Weight-based  
dosing

#### Currently on once-daily basal insulin

**1:1**

conversion  
to start

#### Taking twice-daily: NPH or insulin detemir

**80%**

of total daily  
dose

### 2. Set titration goals based on patient needs and history<sup>1,2\*</sup>

#### Individualize



based on  
FPG goal

#### Adjust and titrate



no more frequently than every 3-4 days  
to reduce the risk of hypoglycemia

**Scan now to use the Toujeo Dosing Calculator and get a suggested starting dose for insulin-naïve patients.**



Open your  
camera app



Center the code  
on your screen



Tap on the  
link pop-up



More or less stringent goals may be appropriate for individual patients

- Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results, and glycemic control goal
- In clinical trials, patients started on, or changed to Toujeo required a higher dose than patients controlled on Lantus<sup>®1</sup>
- Monitor glucose frequently in the first few weeks of therapy

The maximum glucose-lowering effect of a dose of Toujeo may take 5 days, and the first Toujeo dose may be insufficient to cover metabolic needs in the first 24 hours of use. The dosage of other antidiabetic drugs may need to be adjusted when starting Toujeo to minimize the risk of hypoglycemia. View additional dosing information in the full Prescribing Information.

\* ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.<sup>2</sup>

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.

## Important Safety Information

### Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

### Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus<sup>®</sup>. The concentration of insulin glargine in Toujeo is 300 units per mL.

**Please see full Important Safety Information on pages 2-3.**

**Please click [here](#) or visit where you downloaded this information for full Prescribing Information for Toujeo.**

# Important Safety Information

## Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

## Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

**Insulin pens and needles must never be shared between patients. Do NOT reuse needles.**

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.

Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

## Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

## Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

# Important Safety Information for Toujeo SoloStar® and Toujeo Max SoloStar®

Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe.

**Please click [here](#) or visit where you downloaded this information for full Prescribing Information for Toujeo.**

**References:** 1. Toujeo Prescribing Information. 2. American Diabetes Association. *Diabetes Care*. 2018;41(suppl 1):S1-S135.

# PRESCRIBING TOUJEO®

## Writing for Ray

Ray is new to basal insulin and starting Toujeo. Here's how his doctor writes his 30-day supply based on weight.

**Prescription Summary**

Prescriber Location:  [edit default location](#)

**Prescription**

For: Ray  
(F) D.O.B.: 07/23/1981

**Rx** Toujeo  
Weight: 204 lbs  
Starting dose: 18 Units/day  
Boxes to dispense: 1 box/month of Toujeo SoloStar

By: John D. Doe, MD on 09/01/2019

For ePrescribing, prescription will be electronically sent to the following pharmacy:  
Hometown pharmacy [change pharmacy](#)  
1234 Main Street  
Anytown, CA 94110  
Phone: 123-456-7899  
Fax: 123-456-6789

[ePrescribe & Print Pt Copy](#) [ePrescribe Only](#) [Print Paper Rx](#) [Cancel](#)

For example purposes only

## Reminders:



Ensure that patients have a **separate** prescription for pen needles



Remind patients to **not re-use** needles, not to share pens and needles

## Important Safety Information

### Warnings and Precautions (cont'd)

**Insulin pens and needles must never be shared between patients. Do NOT reuse needles.**

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

**Please see full Important Safety Information on pages 2-3.**

**Please click [here](#) or visit where you downloaded this information for full Prescribing Information for Toujeo.**

## Here's a dose-to-box conversion cheat sheet

### Toujeo SoloStar

Units per day	Boxes Required
Up to 45	1
46-90	2
91-135	3

### Toujeo Max SoloStar

Units per day	Boxes Required
Up to 60	1
61-120	2
121-180	3

Hypothetical patient.



**Toujeo®**  
insulin glargine injection 300 Units/mL